Analyst Research

Report Title Price
Provider: Thomson Reuters Stock Report
$25.00
Provider: Stock Traders Daily
$20.00
Provider: New Constructs, LLC
$25.00
Provider: Jefferson Research
$20.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

DepoMed Inc reiterates FY 2014 outlook


Thursday, 8 May 2014 04:05pm EDT 

DepoMed Inc:Reiterates its financial outlook for FY 2014.Expects FY 2014 total revenues of about $200 mln to $215 mln, which includes non-cash revenues related to the PDL transaction and $15 mln in potential milestones from Mallinckrodt.Expects FY 2014 GAAP earnings per share (EPS) of about $0.21 to $0.36 per share, which includes the non-cash PDL revenues and non-cash PDL interest expense.Expects FY 2014 non-GAAP adjusted earnings per share of break-even to $0.16 per share.FY 2014 revenue of $210 mln and EPS of $0.31 - Thomson Reuters I/B/E/S. 

Company Quote

16.16
0.44 +2.80%
3:24pm EST